Clinical Trial Update: Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update investigating regorafenib in combination with XELOX as a second-line treatment for metastatic colorectal cancer (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: China Medical University, China | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: UNKNOWN